PeriPath — Symptom-to-Care Navigator for Perimenopause, Built for the “No Single Test” Reality

The Problem

Perimenopause is a classic “high pain, low clarity” market.

Women often know something is wrong long before they know what it is. The care system makes this worse: symptoms are broad, hormone levels fluctuate, and many clinicians still rely on outdated or over-simplified heuristics.

The core product insight is embedded directly in the medical guidance:

• Mayo Clinic: there is no single test to confirm perimenopause, and hormone testing is usually not that helpful because levels fluctuate unpredictably.
• WEF: women spend 25% more time in poor health than men, and closing the women’s health gap could add $1T annually to the global economy.
• WEF / BCG (2026): only 6% of private health investment goes to women’s health despite the scale of the opportunity.
• Midi Health (Feb 2026) reached a $1B valuation after starting with perimenopause / menopause care, proving demand is real and monetizable.
• Capital Cell (2026): women’s health investment grew 55% YoY to $2.6B in 2024, while Europe’s femtech market hit €2.4B.